+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Allergic Rhinitis Drugs Market by Distribution Channel, Patient Age Group, Dosage Form, Route Of Administration, Drug Class - Global Forecast to 2030- Product Image
Allergic Rhinitis Drugs Market by Distribution Channel, Patient Age Group, Dosage Form, Route Of Administration, Drug Class - Global Forecast to 2030- Product Image
Sale

Allergic Rhinitis Drugs Market by Distribution Channel, Patient Age Group, Dosage Form, Route Of Administration, Drug Class - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4905052
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Allergic Rhinitis Drugs Market grew from USD 4.97 billion in 2024 to USD 5.22 billion in 2025. It is expected to continue growing at a CAGR of 4.80%, reaching USD 6.59 billion by 2030.

Setting the Stage for Allergic Rhinitis Drug Market

Allergic rhinitis represents one of the most prevalent chronic conditions globally, affecting hundreds of millions of individuals each year and significantly impacting quality of life. Recognizing the persistent burden on healthcare systems and patients alike, pharmaceutical stakeholders have accelerated innovation in therapies ranging from over‐the‐counter decongestants to novel biologics. This executive summary distills critical developments, structural shifts, and expert insights that define the current competitive landscape.

As industry leaders and decision makers seek clarity amid rapid regulatory changes, evolving patient demands, and supply chain complexities, this overview provides a clear lens through which to examine market drivers and challenges. It lays the foundation for informed strategy formulation, enabling stakeholders to navigate dynamic market forces and capitalize on emerging opportunities in the treatment of allergic rhinitis.

Evolving Dynamics Redefining Treatment Paradigms

In recent years, the allergic rhinitis arena has witnessed a profound transformation, driven by breakthroughs in pharmacology and an intensified focus on personalized medicine. Advances in intranasal corticosteroid formulations have improved patient adherence by minimizing dosing frequency while maintaining therapeutic efficacy. Simultaneously, the development of targeted antihistamine therapies, including second‐generation H1 antagonists, has reduced systemic side effects and enhanced patient satisfaction.

Digital health platforms now facilitate real‐time symptom tracking, empowering patients to better manage triggers and treatment regimens. Telemedicine integration has expanded access to specialist consultations, reshaping diagnostic workflows and encouraging earlier intervention. Moreover, regulatory bodies have signaled greater openness to combination therapies, potentially expediting the approval of multi‐modal approaches. As these shifts converge, pharmaceutical companies must adapt to a landscape where innovation, patient engagement, and regulatory agility are inseparable.

United States Tariffs Shaping 2025 Supply Chains

The implementation of new United States tariffs in 2025 has introduced material cost pressures across the allergic rhinitis supply chain. Key active pharmaceutical ingredients sourced internationally are now subject to higher import duties, prompting manufacturers to reassess sourcing strategies and supplier relationships. This cumulative impact has translated into incremental production expenses, which in turn affect pricing negotiations with payers and distribution partners.

In response, several firms have initiated nearshoring initiatives, establishing local API manufacturing sites to mitigate tariff exposure and ensure supply continuity. Others have engaged in collaborative procurement consortia to lock in favorable raw material contracts. Although these measures involve significant capital investment, they are essential to preserving margin integrity and shielding patients from abrupt price increases. Overall, the tariff environment underscores the need for proactive, resilient supply chain management.

Unearthing Distinct Market Segments for Precise Targeting

Analysis based on distribution channel reveals that hospital pharmacies maintain a central role in the delivery of acute care regimens, particularly for severe rhinitis presentations requiring injectable agents. Concurrently, online pharmacies are experiencing rapid growth by offering convenience and discreet access to both prescription and over‐the‐counter treatments. While retail pharmacies remain the primary touchpoint for self‐care products, specialty pharmacies have carved out a niche in supporting complex therapies and patient education.

When segmenting by patient age group, pediatric populations demand age‐appropriate formulations and careful dosing considerations to ensure safety and adherence. Adult cohorts prioritize rapid symptom relief combined with minimal sedation effects, and geriatric patients often present with comorbidities that influence drug selection and administration preferences. Within dosage form analysis, eye drop options differentiate between single‐use vials for sterility and multi‐use containers for cost efficiency, whereas injectable therapies must balance intramuscular and subcutaneous delivery based on onset of action and patient comfort. The nasal spray domain continues to expand through both dry powder devices that deliver consistent dosing without propellants and metered‐dose systems that incorporate user feedback for precise administration. Oral solutions illustrate a divide between liquid concentrates favored for customizable dosing and ready‐to‐use preparations that simplify compliance. Tablets persist in two key formats, with immediate‐release variants offering quick relief and extended‐release formulations supporting 24‐hour control.

Exploring routes of administration underscores nasal delivery as the predominant choice for localized relief, while ocular applications address comorbid eye symptoms in allergic rhinitis sufferers. Oral administration remains critical for system‐wide intervention, and parenteral methods-divided into intramuscular, intravenous, and subcutaneous pathways-serve niche indications and rapid‐onset scenarios. Drug class segmentation highlights persistent demand for decongestants, where phenylephrine appeals to patients seeking rapid effect and pseudoephedrine retains its strong efficacy profile. H1 antihistamines show a clear shift toward second‐generation molecules due to their favorable safety and tolerability, and intranasal corticosteroids continue to diversify with budesonide, fluticasone, mometasone, and triamcinolone options. Leukotriene receptor antagonists such as montelukast and zafirlukast sustain their role in adjunctive therapy, whereas mast cell stabilizers-exemplified by cromolyn sodium and nedocromil-remain important for preventive regimens.

Regional Nuances Driving Treatment Adoption Patterns

In the Americas, advanced healthcare infrastructure, extensive insurance coverage, and a strong generics market create a competitive environment in which manufacturers differentiate through value‐added services and patient support programs. By contrast, in Europe, Middle East & Africa, market heterogeneity arises from regulatory variations across the European Union, emerging opportunities in Gulf Cooperation Council states, and infrastructure limitations in parts of Africa. Companies navigating this region must tailor market entry strategies to local reimbursement protocols and distribution logistics.

Meanwhile, Asia‐Pacific is characterized by rapid urbanization, rising disposable incomes, and government initiatives to expand healthcare access, fostering both branded and biosimilar product growth. Market leaders are forming local partnerships to address diverse regulatory requirements and cultural factors influencing treatment adherence. Across all regions, localized marketing campaigns and region-specific clinical studies are emerging as critical tactics to capture share in varied regulatory and competitive landscapes.

Competitive Landscape Insights from Leading Innovators

Leading pharmaceutical innovators have intensified investments in next-generation molecules and device technologies to maintain competitive advantage. Patent expirations within core H1 antihistamine portfolios have spurred strategic acquisitions and licensing agreements, enabling rapid portfolio diversification. Several major players have also partnered with digital health firms to integrate symptom‐tracking applications with medication delivery devices, strengthening patient engagement and adherence monitoring.

Manufacturers are optimizing manufacturing footprints by expanding biologics capabilities, particularly in regions with favorable tax incentives and skilled workforces. Meanwhile, smaller specialized companies are carving out niches through targeted research on novel mast cell stabilizers and non-steroidal intranasal agents. Collaborations between global leaders and regional firms are reshaping supply networks, ensuring rapid market access and compliance with evolving local regulations. Collectively, these strategies illustrate a competitive landscape driven by innovation, strategic partnerships, and geographical agility.

Strategic Imperatives for Industry Leadership

Industry participants should prioritize supply chain resilience by establishing diversified sourcing arrangements and pursuing localized production partnerships to mitigate tariff and geopolitical risks. Simultaneously, investing in patient-centric drug delivery systems that enhance ease of use will foster loyalty and differentiate offerings in a crowded market. Embracing digital engagement tools, from telemedicine integrations to mobile symptom‐tracking apps, can unlock actionable real-world data and strengthen patient outcomes.

Moreover, organizations must explore strategic alliances, whether through licensing agreements or co-development initiatives, to accelerate the introduction of novel therapeutic combinations. Targeted pricing strategies that reflect regional economic dynamics and reimbursement frameworks will optimize access while preserving profitability. Finally, embedding agility into decision-making processes-through scenario planning and dynamic portfolio review-will enable swift responses to regulatory shifts and emerging competitive threats.

Comprehensive Research Approach and Data Integrity

This study synthesizes insights from a rigorous, multi-tiered research framework combining primary interviews with industry executives, formulary decision makers, and clinical experts alongside exhaustive secondary analysis of regulatory filings, patent databases, and peer-reviewed literature. Proprietary data modelling techniques ensured the accurate mapping of distribution networks and prescribing patterns.

Each data point underwent rigorous validation through triangulation across multiple sources to guarantee reliability and integrity. Detailed segmentation analysis was conducted using standardized taxonomies for distribution channel, patient demographics, dosage form, route of administration, and pharmacological class. Regional market assessments incorporated local reimbursement policies and infrastructure considerations. This transparent, reproducible methodology underpins the credibility of our findings and supports robust strategic decision making.

Synthesis of Insights and Forward-Looking Perspective

The intersection of evolving therapeutic innovations, regulatory landscapes, and geopolitical factors defines a pivotal moment in the allergic rhinitis drugs market. Stakeholders that harness detailed segment insights, anticipate tariff impacts, and tailor regional strategies will be best positioned to capture growth and deliver enhanced patient outcomes. Collaboration across the value chain-spanning supply partners, healthcare providers, and digital health innovators-will be essential to unlocking sustainable advantage.

Ultimately, the capacity to align strategic investments with real-time market intelligence will determine success in an environment of accelerating change. By integrating the recommendations outlined herein, industry leaders can advance toward more resilient, patient-focused portfolio models while driving long-term commercial performance.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
    • Specialty Pharmacy
  • Patient Age Group
    • Adult
    • Geriatric
    • Pediatric
  • Dosage Form
    • Eye Drop
      • Multi Use
      • Single Use
    • Injection
      • Intramuscular
      • Subcutaneous
    • Nasal Spray
      • Dry Powder
      • Metered Dose
    • Oral Solution
      • Liquid Concentrate
      • Ready To Use
    • Tablet
      • Extended Release
      • Immediate Release
  • Route Of Administration
    • Nasal
    • Ocular
    • Oral
    • Parenteral
      • Intramuscular
      • Intravenous
      • Subcutaneous
  • Drug Class
    • Decongestants
      • Phenylephrine
      • Pseudoephedrine
    • H1 Antihistamines
      • First Generation
      • Second Generation
    • Intranasal Corticosteroids
      • Budesonide
      • Fluticasone
      • Mometasone
      • Triamcinolone
    • Leukotriene Receptor Antagonists
      • Montelukast
      • Zafirlukast
    • Mast Cell Stabilizers
      • Cromolyn Sodium
      • Nedocromil
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Sanofi SA
  • Bayer AG
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Novartis International AG
  • Boehringer Ingelheim International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • AstraZeneca plc

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Allergic Rhinitis Drugs Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacy
8.3. Online Pharmacy
8.4. Retail Pharmacy
8.5. Specialty Pharmacy
9. Allergic Rhinitis Drugs Market, by Patient Age Group
9.1. Introduction
9.2. Adult
9.3. Geriatric
9.4. Pediatric
10. Allergic Rhinitis Drugs Market, by Dosage Form
10.1. Introduction
10.2. Eye Drop
10.2.1. Multi Use
10.2.2. Single Use
10.3. Injection
10.3.1. Intramuscular
10.3.2. Subcutaneous
10.4. Nasal Spray
10.4.1. Dry Powder
10.4.2. Metered Dose
10.5. Oral Solution
10.5.1. Liquid Concentrate
10.5.2. Ready To Use
10.6. Tablet
10.6.1. Extended Release
10.6.2. Immediate Release
11. Allergic Rhinitis Drugs Market, by Route Of Administration
11.1. Introduction
11.2. Nasal
11.3. Ocular
11.4. Oral
11.5. Parenteral
11.5.1. Intramuscular
11.5.2. Intravenous
11.5.3. Subcutaneous
12. Allergic Rhinitis Drugs Market, by Drug Class
12.1. Introduction
12.2. Decongestants
12.2.1. Phenylephrine
12.2.2. Pseudoephedrine
12.3. H1 Antihistamines
12.3.1. First Generation
12.3.2. Second Generation
12.4. Intranasal Corticosteroids
12.4.1. Budesonide
12.4.2. Fluticasone
12.4.3. Mometasone
12.4.4. Triamcinolone
12.5. Leukotriene Receptor Antagonists
12.5.1. Montelukast
12.5.2. Zafirlukast
12.6. Mast Cell Stabilizers
12.6.1. Cromolyn Sodium
12.6.2. Nedocromil
13. Americas Allergic Rhinitis Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Allergic Rhinitis Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Allergic Rhinitis Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Johnson & Johnson
16.3.2. GlaxoSmithKline plc
16.3.3. Sanofi SA
16.3.4. Bayer AG
16.3.5. Merck & Co., Inc.
16.3.6. Pfizer Inc.
16.3.7. Novartis International AG
16.3.8. Boehringer Ingelheim International GmbH
16.3.9. Teva Pharmaceutical Industries Ltd.
16.3.10. AstraZeneca plc
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ALLERGIC RHINITIS DRUGS MARKET MULTI-CURRENCY
FIGURE 2. ALLERGIC RHINITIS DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. ALLERGIC RHINITIS DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ALLERGIC RHINITIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ALLERGIC RHINITIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ALLERGIC RHINITIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ALLERGIC RHINITIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ALLERGIC RHINITIS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ALLERGIC RHINITIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ALLERGIC RHINITIS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY EYE DROP, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY MULTI USE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY SINGLE USE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY EYE DROP, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY NASAL SPRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DRY POWDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY METERED DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY LIQUID CONCENTRATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY READY TO USE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY NASAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY OCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DECONGESTANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PHENYLEPHRINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PSEUDOEPHEDRINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DECONGESTANTS, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY H1 ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY H1 ANTIHISTAMINES, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INTRANASAL CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY BUDESONIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY FLUTICASONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY MOMETASONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY TRIAMCINOLONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INTRANASAL CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY LEUKOTRIENE RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY MONTELUKAST, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ZAFIRLUKAST, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY LEUKOTRIENE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY MAST CELL STABILIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY CROMOLYN SODIUM, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY NEDOCROMIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS ALLERGIC RHINITIS DRUGS MARKET SIZE, BY EYE DROP, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS ALLERGIC RHINITIS DRUGS MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS ALLERGIC RHINITIS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DECONGESTANTS, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS ALLERGIC RHINITIS DRUGS MARKET SIZE, BY H1 ANTIHISTAMINES, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INTRANASAL CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS ALLERGIC RHINITIS DRUGS MARKET SIZE, BY LEUKOTRIENE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS ALLERGIC RHINITIS DRUGS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS ALLERGIC RHINITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY EYE DROP, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DECONGESTANTS, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY H1 ANTIHISTAMINES, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INTRANASAL CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY LEUKOTRIENE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 102. CANADA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. CANADA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 104. CANADA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 105. CANADA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY EYE DROP, 2018-2030 (USD MILLION)
TABLE 106. CANADA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 107. CANADA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 108. CANADA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2030 (USD MILLION)
TABLE 109. CANADA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 110. CANADA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. CANADA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 112. CANADA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 113. CANADA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DECONGESTANTS, 2018-2030 (USD MILLION)
TABLE 114. CANADA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY H1 ANTIHISTAMINES, 2018-2030 (USD MILLION)
TABLE 115. CANADA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INTRANASAL CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 116. CANADA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY LEUKOTRIENE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 117. CANADA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2030 (USD MILLION)
TABLE 118. MEXICO ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. MEXICO ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 120. MEXICO ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 121. MEXICO ALLERGIC RHINITIS DRUGS MARKET SIZE, BY EYE DROP, 2018-2030 (USD MILLION)
TABLE 122. MEXICO ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 123. MEXICO ALLERGIC RHINITIS DRUGS MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 124. MEXICO ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2030 (USD MILLION)
TABLE 125. MEXICO ALLERGIC RHINITIS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 126. MEXICO ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. MEXICO ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 128. MEXICO ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 129. MEXICO ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DECONGESTANTS, 2018-2030 (USD MILLION)
TABLE 130. MEXICO ALLERGIC RHINITIS DRUGS MARKET SIZE, BY H1 ANTIHISTAMINES, 2018-2030 (USD MILLION)
TABLE 131. MEXICO ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INTRANASAL CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 132. MEXICO ALLERGIC RHINITIS DRUGS MARKET SIZE, BY LEUKOTRIENE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 133. MEXICO ALLERGIC RHINITIS DRUGS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY EYE DROP, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DECONGESTANTS, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY H1 ANTIHISTAMINES, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INTRANASAL CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY LEUKOTRIENE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL ALLERGIC RHINITIS DRUGS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2030 (USD MILLION)
TABLE 150. ARGENTINA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 151. ARGENTINA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 152. ARGENTINA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 153. ARGENTINA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY EYE DROP, 2018-2030 (USD MILLION)
TABLE 154. ARGENTINA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 155. ARGENTINA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 156. ARGENTINA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2030 (USD MILLION)
TABLE 157. ARGENTINA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 158. ARGENTINA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. ARGENTINA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 160. ARGENTINA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 161. ARGENTINA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DECONGESTANTS, 2018-2030 (USD MILLION)
TABLE 162. ARGENTINA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY H1 ANTIHISTAMINES, 2018-2030 (USD MILLION)
TABLE 163. ARGENTINA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INTRANASAL CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 164. ARGENTINA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY LEUKOTRIENE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 165. ARGENTINA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2030 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY EYE DROP, 2018-2030 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DECONGESTANTS, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY H1 ANTIHISTAMINES, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INTRANASAL CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY LEUKOTRIENE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2030 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. UNITED KINGDOM ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM ALLERGIC RHINITIS DRUGS MARKET SIZE, BY EYE DROP, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM ALLERGIC RHINITIS DRUGS MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM ALLERGIC RHINITIS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 194. UNITED KINGDOM ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DECONGESTANTS, 2018-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM ALLERGIC RHINITIS DRUGS MARKET SIZE, BY H1 ANTIHISTAMINES, 2018-2030 (USD MILLION)
TABLE 196. UNITED KINGDOM ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INTRANASAL CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM ALLERGIC RHINITIS DRUGS MARKET SIZE, BY LEUKOTRIENE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 198. UNITED KINGDOM ALLERGIC RHINITIS DRUGS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2030 (USD MILLION)
TABLE 199. GERMANY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. GERMANY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 201. GERMANY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 202. GERMANY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY EYE DROP, 2018-2030 (USD MILLION)
TABLE 203. GERMANY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 204. GERMANY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 205. GERMANY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2030 (USD MILLION)
TABLE 206. GERMANY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 207. GERMANY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. GERMANY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 209. GERMANY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 210. GERMANY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DECONGESTANTS, 2018-2030 (USD MILLION)
TABLE 211. GERMANY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY H1 ANTIHISTAMINES, 2018-2030 (USD MILLION)
TABLE 212. GERMANY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INTRANASAL CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 213. GERMANY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY LEUKOTRIENE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 214. GERMANY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2030 (USD MILLION)
TABLE 215. FRANCE ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. FRANCE ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 217. FRANCE ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 218. FRANCE ALLERGIC RHINITIS DRUGS MARKET SIZE, BY EYE DROP, 2018-2030 (USD MILLION)
TABLE 219. FRANCE ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 220. FRANCE ALLERGIC RHINITIS DRUGS MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 221. FRANCE ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2030 (USD MILLION)
TABLE 222. FRANCE ALLERGIC RHINITIS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 223. FRANCE ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. FRANCE ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 225. FRANCE ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 226. FRANCE ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DECONGESTANTS, 2018-2030 (USD MILLION)
TABLE 227. FRANCE ALLERGIC RHINITIS DRUGS MARKET SIZE, BY H1 ANTIHISTAMINES, 2018-2030 (USD MILLION)
TABLE 228. FRANCE ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INTRANASAL CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 229. FRANCE ALLERGIC RHINITIS DRUGS MARKET SIZE, BY LEUKOTRIENE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 230. FRANCE ALLERGIC RHINITIS DRUGS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY EYE DROP, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 236. RUSSIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 237. RUSSIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2030 (USD MILLION)
TABLE 238. RUSSIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 239. RUSSIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 240. RUSSIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 241. RUSSIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 242. RUSSIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DECONGESTANTS, 2018-2030 (USD MILLION)
TABLE 243. RUSSIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY H1 ANTIHISTAMINES, 2018-2030 (USD MILLION)
TABLE 244. RUSSIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INTRANASAL CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 245. RUSSIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY LEUKOTRIENE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 246. RUSSIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2030 (USD MILLION)
TABLE 247. ITALY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. ITALY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 249. ITALY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 250. ITALY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY EYE DROP, 2018-2030 (USD MILLION)
TABLE 251. ITALY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 252. ITALY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 253. ITALY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2030 (USD MILLION)
TABLE 254. ITALY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 255. ITALY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. ITALY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 257. ITALY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 258. ITALY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DECONGESTANTS, 2018-2030 (USD MILLION)
TABLE 259. ITALY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY H1 ANTIHISTAMINES, 2018-2030 (USD MILLION)
TABLE 260. ITALY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INTRANASAL CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 261. ITALY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY LEUKOTRIENE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 262. ITALY ALLERGIC RHINITIS DRUGS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2030 (USD MILLION)
TABLE 263. SPAIN ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 264. SPAIN ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 265. SPAIN ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 266. SPAIN ALLERGIC RHINITIS DRUGS MARKET SIZE, BY EYE DROP, 2018-2030 (USD MILLION)
TABLE 267. SPAIN ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 268. SPAIN ALLERGIC RHINITIS DRUGS MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 269. SPAIN ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2030 (USD MILLION)
TABLE 270. SPAIN ALLERGIC RHINITIS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 271. SPAIN ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 272. SPAIN ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 273. SPAIN ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 274. SPAIN ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DECONGESTANTS, 2018-2030 (USD MILLION)
TABLE 275. SPAIN ALLERGIC RHINITIS DRUGS MARKET SIZE, BY H1 ANTIHISTAMINES, 2018-2030 (USD MILLION)
TABLE 276. SPAIN ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INTRANASAL CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 277. SPAIN ALLERGIC RHINITIS DRUGS MARKET SIZE, BY LEUKOTRIENE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 278. SPAIN ALLERGIC RHINITIS DRUGS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY EYE DROP, 2018-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2030 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DECONGESTANTS, 2018-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY H1 ANTIHISTAMINES, 2018-2030 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INTRANASAL CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY LEUKOTRIENE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES ALLERGIC RHINITIS DRUGS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2030 (USD MILLION)
TABLE 295. SAUDI ARABIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 296. SAUDI ARABIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 298. SAUDI ARABIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY EYE DROP, 2018-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 300. SAUDI ARABIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2030 (USD MILLION)
TABLE 302. SAUDI ARABIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 304. SAUDI ARABIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 306. SAUDI ARABIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DECONGESTANTS, 2018-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY H1 ANTIHISTAMINES, 2018-2030 (USD MILLION)
TABLE 308. SAUDI ARABIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INTRANASAL CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY LEUKOTRIENE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 310. SAUDI ARABIA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2030 (USD MILLION)
TABLE 311. SOUTH AFRICA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 312. SOUTH AFRICA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 314. SOUTH AFRICA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY EYE DROP, 2018-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 316. SOUTH AFRICA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2030 (USD MILLION)
TABLE 318. SOUTH AFRICA ALLERGIC RHINITIS DRUGS MARKET SIZE, BY TABLET, 2018-2030

Companies Mentioned

The companies profiled in this Allergic Rhinitis Drugs market report include:
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Sanofi SA
  • Bayer AG
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Novartis International AG
  • Boehringer Ingelheim International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • AstraZeneca plc

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages199
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 5.22 Billion
Forecasted Market Value ( USD ) by 2030 $ 6.59 Billion
Compound Annual Growth Rate4.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Allergic Rhinitis Drug Market by Treatment Type, Disease Type, Drug, Route of Administration, Distribution Channel - Global Market Size, Segmental Analysis, Regional Overview, Company Share Analysis, Leading Company Profiles and Market Forecast, 2025-2035 - Product Image

Allergic Rhinitis Drug Market by Treatment Type, Disease Type, Drug, Route of Administration, Distribution Channel - Global Market Size, Segmental Analysis, Regional Overview, Company Share Analysis, Leading Company Profiles and Market Forecast, 2025-2035

  • Report
  • 210 Pages
  • Global
From
Allergic Rhinitis Drugs - Global Strategic Business Report - Product Image

Allergic Rhinitis Drugs - Global Strategic Business Report

  • Report
  • 563 Pages
  • Global
From
Allergic Rhinitis Drugs Market Report 2025 - Product Image

Allergic Rhinitis Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Allergic Rhinitis Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Allergic Rhinitis Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 155 Pages
  • Global
From
Allergic Rhinitis Treatment Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Product Type - Product Image

Allergic Rhinitis Treatment Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Product Type

  • Report
  • 89 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.